Literature DB >> 14671050

The variability and accurate assessment of microinflammation in haemodialysis patients.

George Tsirpanlis1, Pantelis Bagos, Dimitris Ioannou, Aliki Bleta, Ioanna Marinou, Antonis Lagouranis, Stylianos Chatzipanagiotou, Chrysoula Nicolaou.   

Abstract

BACKGROUND: Systemic microinflammation is correlated with atherosclerosis. It needs a reliable assessment. This study explores the temporal variations of three inflammatory indexes [C-reactive protein (CRP), serum amyloid A (SAA) and interleukin-6 (IL-6)] in a period free of clinical events and tests the reliability of their multiple measurements for the assessment of microinflammation in haemodialysis (HD) patients, a population at high risk of atherosclerotic cardiovascular disease.
METHODS: For 4 months, serum CRP, SAA and IL-6 were measured in 29 HD patients during the weeks they were free of inflammatory clinical events (> or =12 measurements for each index in every patient). The components of the variance as well as the reliability of two to five measurements for each index, aimed at assessing microinflammation precisely, were computed.
RESULTS: The median (interquartile range) of CRP was 2.3 (0.9-4.9) mg/l, of SAA 3.7 (2.1-9.3) mg/l and of IL-6 4.4 (2.2-7.7) pg/ml. Patients were approximately equally distributed between three groups of low, intermediate and high variability for each index. The contribution of intraindividual (biological) variation to the total of variance was 71.3%, 69.3% and 86.7% for CRP, SAA and IL-6, respectively (higher than in all other similar studies in healthy populations). Using two measurements, the estimated reliability was 57-68% for CRP in two-thirds of the patients (comparable with that found in healthy subjects) and 57% for SAA and IL-6 in only one-third of the patients. Increasing the number of measurements up to five did not change the reliability.
CONCLUSIONS: Individual factors significantly influence the levels of inflammatory indexes in HD patients in periods free of inflammatory clinical events. The mean of two weekly CRP measurements, but not of SAA or IL-6, seems to assess microinflammation in most patients with a sufficient reliability.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14671050     DOI: 10.1093/ndt/gfg486

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  14 in total

1.  Serum amyloid A in uremic HDL promotes inflammation.

Authors:  Thomas Weichhart; Chantal Kopecky; Markus Kubicek; Michael Haidinger; Dominik Döller; Karl Katholnig; Cacang Suarna; Philipp Eller; Markus Tölle; Christopher Gerner; Gerhard J Zlabinger; Markus van der Giet; Walter H Hörl; Roland Stocker; Marcus D Säemann
Journal:  J Am Soc Nephrol       Date:  2012-01-26       Impact factor: 10.121

2.  Identification and treatment of symptoms associated with inflammation in medically ill patients.

Authors:  Robert Dantzer; Lucile Capuron; Michael R Irwin; Andrew H Miller; Helene Ollat; Victor Hugh Perry; Sarah Rousey; Raz Yirmiya
Journal:  Psychoneuroendocrinology       Date:  2007-12-03       Impact factor: 4.905

3.  Precision of biomarkers to define chronic inflammation in CKD.

Authors:  Robert LaClair; Kalisha O'Neal; Susan Ofner; Marcelo J Sosa; Carlos A Labarrere; Sharon M Moe
Journal:  Am J Nephrol       Date:  2008-05-28       Impact factor: 3.754

4.  High mobility group box protein-1 correlates with microinflammatory state and nutritional status in continuous ambulatory peritoneal dialysis patients.

Authors:  Nan Zhu; Weijie Yuan; Yi Zhou; Jun Liu; Jinfang Bao; Jing Hao; Wen Miao
Journal:  J Artif Organs       Date:  2011-03-26       Impact factor: 1.731

Review 5.  Monitoring of inflammation in patients on dialysis: forewarned is forearmed.

Authors:  Christiaan L Meuwese; Peter Stenvinkel; Friedo W Dekker; Juan J Carrero
Journal:  Nat Rev Nephrol       Date:  2011-03       Impact factor: 28.314

6.  Effect of membrane permeability on inflammation and arterial stiffness: a randomized trial.

Authors:  Philip Kam-Tao Li; Yuk Lun Cheng; Chi Bon Leung; Cheuk Chun Szeto; Kai Ming Chow; Bonnie Ching-Ha Kwan; Esther Siu-Chun Ng; Queenie Wing-Yi Fok; Yuet Ling Poon; Alex Wai-Yin Yu
Journal:  Clin J Am Soc Nephrol       Date:  2010-03-04       Impact factor: 8.237

7.  IL-6 levels, nutritional status, and mortality in prevalent hemodialysis patients.

Authors:  Ilia Beberashvili; Inna Sinuani; Ada Azar; Hila Yasur; Gregory Shapiro; Leonid Feldman; Zhan Averbukh; Joshua Weissgarten
Journal:  Clin J Am Soc Nephrol       Date:  2011-08-18       Impact factor: 8.237

8.  Associations of interleukin-6, C-reactive protein and serum amyloid A with mortality in haemodialysis patients.

Authors:  James B Wetmore; David H Lovett; Adriana M Hung; Galen Cook-Wiens; Jonathan D Mahnken; Saunak Sen; Kirsten L Johansen
Journal:  Nephrology (Carlton)       Date:  2008-09-25       Impact factor: 2.506

Review 9.  Nutritional and anti-inflammatory interventions in chronic heart failure.

Authors:  Kamyar Kalantar-Zadeh; Stefan D Anker; Tamara B Horwich; Gregg C Fonarow
Journal:  Am J Cardiol       Date:  2008-06-02       Impact factor: 2.778

10.  Assessment of myeloperoxidase and oxidative alpha1-antitrypsin in patients on hemodialysis.

Authors:  Hirokazu Honda; Masashi Ueda; Shiho Kojima; Shinichi Mashiba; Yuki Hirai; Nozomu Hosaka; Hiroki Suzuki; Masanori Mukai; Makoto Watanabe; Keiko Takahashi; Kanji Shishido; Tadao Akizawa
Journal:  Clin J Am Soc Nephrol       Date:  2009-01-07       Impact factor: 8.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.